Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
by andreas lønstrup, translated by catherine brett
The reimbursement committee under the Danish Medicines Agency has recommended that Novo Nordisk’s obesity drug Wegovy is not granted general conditional reimbursement. This is the second time that the council has taken this stance.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
